Krystal Biotech (BSP:K1YS34) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:K1YS34 Krystal Biotech Inc BSP:K1YS34
54 GF Score
Price R$44.80
GF Value R$40.31
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech FFO?

FFO (Funds from operations) only applies to REITs.

BSP:K1YS34
54GF Score
Krystal Biotech Inc BSP:K1YS34
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Krystal Biotech (BSP:K1YS34) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of R$44.80 is trading 11.1% above its estimated GF Value™ of R$40.31.

Key valuation signals for BSP:K1YS34:

  • FFO:
  • GF Value™: R$40.31 vs. price of R$44.80 (11.1% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the BSP:K1YS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
54GF Score

Get the complete analysis for BSP:K1YS34

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$44.80
Price
R$40.31
GF Value